What is more, administration of PT2385, a small molecule inhibitor targeting HIF-2α and restoring the expression of YTHDF2, also exhibits favorable effects in treating HCC cells both in vitro and in vivo. This evidence concerns the gene YTHDF2 and hepatocellular carcinoma.